261 related articles for article (PubMed ID: 14621724)
1. Cytomegalovirus (CMV) excretion as a factor in the severity of CMV disease in kidney and simultaneous kidney and pancreas transplantation.
Pouteil-Noble C; Ecochard R; Bosshard S; Lacavalerie B; Donia A; Landrivon G; Tardy JC; Dubernard JM; Aymard M; Touraine JL
Transpl Int; 1992; 5 Suppl 1():S26-9. PubMed ID: 14621724
[TBL] [Abstract][Full Text] [Related]
2. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus infection in living-donor and cadaveric lung transplantations.
Ohata K; Chen-Yoshikawa TF; Takahashi K; Aoyama A; Motoyama H; Hijiya K; Hamaji M; Menju T; Sato T; Sonobe M; Takakura S; Date H
Interact Cardiovasc Thorac Surg; 2017 Nov; 25(5):710-715. PubMed ID: 29049752
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients.
Pouteil-Noble C; Ecochard R; Landrivon G; Donia-Maged A; Tardy JC; Bosshard S; Colon S; Betuel H; Aymard M; Touraine JL
Transplantation; 1993 Apr; 55(4):851-7. PubMed ID: 8386406
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses.
Toupance O; Bouedjoro-Camus MC; Carquin J; Novella JL; Lavaud S; Wynckel A; Jolly D; Chanard J
Transpl Int; 2000; 13(6):413-9. PubMed ID: 11140239
[TBL] [Abstract][Full Text] [Related]
6. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus infection in a seroendemic renal transplant population: a longitudinal study of virological markers.
Rao M; Finny GJ; Abraham P; Juneja R; Thomas PP; Jacob CK; Sridharan G
Nephron; 2000 Apr; 84(4):367-73. PubMed ID: 10754415
[TBL] [Abstract][Full Text] [Related]
10. IgM antibody detection of ppUL80A and ppUL32 by immunoblotting: an early parameter for recurrent cytomegalovirus infection in renal transplant recipients.
J Med Virol; ; . PubMed ID: 8801292
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
